Interaction-dominant dynamics in human cognition: Beyond 1/?α fluctuation.

It has been suggested that human behavior in general and cognitive performance in particular emerge from coordination between multiple temporal scales. In this article, we provide quantitative support for such a theory of interaction-dominant dynamics in human cognition by using wavelet-based multifractal analysis and accompanying multiplicative cascading process on the response series of 4 different cognitive tasks: simple response, word naming, choice decision, and interval estimation. Results indicated that the major portion of these response series had multiplicative interactions between temporal scales, visible as intermittent periods of large and irregular fluctuations (i.e., a multifractal structure). Comparing 2 component-dominant models of 1/fα fluctuations in cognitive performance with the multiplicative cascading process indicated that the multifractal structure could not be replicated by these component-dominant models. Furthermore, a similar multifractal structure was shown to be present in a model of self-organized criticality in the human nervous system, similar to a spatial extension of the multiplicative cascading process. These results illustrate that a wavelet-based multifractal analysis and the multiplicative cascading process form an appropriate framework to characterize interaction-dominant dynamics in human cognition. This new framework goes beyond the identification of 1/fα power laws and non-Gaussian distributions in response series as used in previous studies. The present article provides quantitative support for a paradigm shift toward interaction-dominant dynamics in human cognition. (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

Communication of medical images, text, and messages in inter-enterprise systems: a case study in Norway.

There is an increasing demand to discuss diagnostic images and reports of difficult cases with experienced staff. A possible solution besides physically transporting patients and material is to use high-speed communication networks to transfer images and reports electronically. With the web application PACSflow we have developed a solution to transfer images, reports, and messages as a single package in a one-step procedure. The PACSflow is an interoperable and standard compliant web-based application, which gives clinicians a user-friendly interface for their work on a daily basis. The solution assumes that the diagnostic images are compatible with the digital imaging and communications in medicine (DICOM) format. The Department of Cardiology at the Rikshospitalet University Hospital in Oslo, Norway, and the Department of Internal Medicine at the S?rlandet Sykehus in Arendal, Norway, are making clinical use of the system. Initial tests indicate that use of PACSflow has reduced the time required to prepare and transfer data by a factor of 3.     

Post-transplant hyperlipidaemia: low-dose lovastatin lowers atherogenic lipids without plasma accumulation of lovastatin

PURPOSE: To compare the therapeutic potential of acarbose, metformin, or placebo as first line treatment in patients with non-insulin-dependent diabetes mellitus (NIDDM). PATIENTS AND METHODS: Ninety-six patients with NIDDM (35-70 years of age, body mass index (BMI) < or = 35 kg/m2, insufficiently treated with diet alone, glycated hemoglobin (HbA1c; 7% to 11%) were randomized into 3 groups and treated for 24 weeks with acarbose, 3 x 100 mg/day, or metformin, 2 x 850 mg/day, or placebo. Efficacy, based on HbA1c (primary efficacy criterion), fasting blood glucose (BG) and insulin, 1 hour postprandial BG and insulin (after standard meal test), postprandial insulin increase, plasma lipid profile, and tolerability, based on subjective symptoms and laboratory values were determined every 6 weeks. Analysis of covariance was performed for endvalues with adjustment on baseline values. Ninety-four patients were valid for efficacy evaluation. RESULTS: Both active drugs showed the same improvement of efficacy criteria compared with placebo. Baseline adjusted means at endpoint were as follows: BG, fasting and 1 hour postprandial, 9.2 mM and 10.9 mM with placebo, 7.6 mM and 8.7 mM with acarbose, and 7.8 mM and 9.0 mM with metformin; HbA1c was 9.8% with placebo, 8.5% with acarbose, and 8.7% with metformin. Comparisons: acarbose versus placebo and metformin versus placebo were statistically significant, but not acarbose versus metformin. No effect on fasting insulin could be observed. Relative postprandial insulin increase was 1.90 with placebo, 1.09 with acarbose, and 1.03 with metformin. Comparisons: acarbose versus placebo and metformin versus placebo were statistically significant, but not acarbose versus metformin. With respect to lipid profile, acarbose was superior to metformin. Low-density lipoprotein (LDL)/high-density lipoprotein (HDL) cholesterol ratio increased by 14.4% with placebo, was unchanged with metformin, but decreased by 26.7% with acarbose. Comparisons: acarbose versus placebo and acarbose versus metformin were statistically significant, but not metformin versus placebo. Slight body weight changes were observed with acarbose (-0.8 kg) and metformin (-0.5 kg), but not with placebo. Acarbose led to mild or moderate intestinal symptoms in 50% of the patients within the first 4 weeks, but in only 13.8% of the patients within the last 4 weeks. CONCLUSIONS: Acarbose and metformin are effective drugs for the first line monotherapy of patients with NIDDM. With respect to plasma lipid profile, especially HDL cholesterol, LDL cholesterol and LDL/HDL cholesterol ratio acarbose may be superior to metformin.